Diagnosis and treatment of sleep disorders: A brief review for clinicians

Dialogues in Clinical Neuroscience

Volumn 5, Issue 4, 2003, Pages 371-388

  Abad, Vivien C ^a   Guilleminault, Christian ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Circadian rhythm disorder; Diagnosis; Excessive somnolence; Insomnia; Parasomnia; Sleep disorder; Treatment

Indexed keywords

4 HYDROXYBUTYRIC ACID; BENZODIAZEPINE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; METHAMPHETAMINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PEMOLINE; PROTRIPTYLINE; PSYCHOSTIMULANT AGENT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZOLPIDEM; ZOPICLONE;

ADOLESCENT; ADULT; CHILD; CIRCADIAN RHYTHM; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; COMA; CONFUSION; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; FALLING; FEEDBACK SYSTEM; HUMAN; HYPERSOMNIA; IMAGERY; INCONTINENCE; INSOMNIA; LABORATORY TEST; MEDITATION; MEMORY DISORDER; META ANALYSIS; NARCOLEPSY; NAUSEA; NIGHT SLEEP; NIGHTMARE; PARASOMNIA; PHYSICAL EXAMINATION; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; REBOUND; RELAXATION TRAINING; REM BEHAVIOR SLEEP DISORDER; REM SLEEP; RESPIRATION DEPRESSION; SEDATION; SHORT SURVEY; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SLEEP TERROR; SLEEP WAKING CYCLE; SLEEP WALKING; SOMNOLENCE; TRAFFIC ACCIDENT;

EID: 0347764575     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (162)

1. Understanding Sleep: Brain Basics. Office of Communications and Public Liaison, National Institute of Neurological Disorders and Stroke, Bethesda, Md. Available at: http://www.ninds.nih.gov/index.htm. Accessed 7 August 2003.
2. Ohayon M, Guilleminault C. Epidemiology of Sleep Disorders. In: Chokroverty S, ed. Sleep Disorders Medicine. Woburn, Mass: Butterworth Heinemann; 1999:301-316.
3. Partinen M, Hublin C. Epidemiology of Sleep Disorders. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia, Pa: WB Saunders; 1979:558-579.
4. American Academy of Sleep Medicine. The International Classification of Sleep Disorders, revised: Diagnostic and Coding Manual. Rochester, Minn: American Academy of Sleep Medicine; 2000.
5. Thorpy M. Classification of Sleep Disorders. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:547-557.
6. Thorpy M. Classification of Sleep Disorders. In: Chokroverty S, ed. Sleep Disorders Medicine. Woburn, Mass: Butterworth Heinemann; 1999:287-300.
7. Reite M, Ruddy J, Nagel K. Concise Guide to Evaluation and Management of Sleep Disorders. Washington, DC: American Psychiatric Publishing; 2002:1-273.
8. Borbely A. Sleep: circadian rhythm vs recovery process. In: Koukou-Lehman M, ed. Functional States of the Brain: their Determinants. Amsterdam: Elsevier/North Holland; 1980:151-161.
9. Zee P, Harsanyi K. Highlights of sleep neuroscience. In: Bowman T, ed. Review of Sleep Medicine. Burlington, Mass: Butterworth Heinemann; 2003:19-39.
10. Silber MH. Neurologic treatment sleep disorders. Neurol Clin. 2001;19:173-186.
11. Elsenbruch S, Thompson JJ, Hamish MJ, Exton MS, Orr WC. Behavioral and physiological sleep characteristics in women with irritable bowel syndrome. Am J Gastroenterol. 2002;97:2306-2314.
12. Moldofsky H. Management of sleep disorders in fibromyalgia. Rheum Dis Clin North Am. 2002;28:173-186.
13. Chokroverty S. Diagnosis and treatment of sleep disorders caused by comorbid disease. Neurology. 2000;54(5 suppl 1):S8-S15.
14. Neubauer D. Sleep problems in the elderly. Am Fam Physician. 1999;59:2551-2560.
15. Chesson, AL Jr, Ferber RA, Fry JM, et al. Practice parameters for the indications for polysomnography and related procedures. Sleep. 1997:406-422.
16. Chesson AL Jr, Ferber RA, Fry JM, et al. The indications for polysomnography and related procedures. Sleep. 1997;20:423-487.
17. Keenan S. Polysomnographic technique: an overview. In: Bowman, ed. Review of Sleep Medicine. Burlington, Mass: Butterworth Heinemann; 2003:107-132.
18. Chervin R. Use of clinical tools and tests in sleep medicine. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:537-543.
19. Thorpy M, Chesson A, Ferber R. et al. Practice parameters for the use of portable recording in the assessment of obstructive sleep apnea. Sleep. 1994;17:372-377.
20. Van Kempeima AR, Rutgers SR, Strijers RL. The value of 1-hour daytime sleep recording in the diagnosis of the sleep apnea syndrome. J Sleep Res. 1993;2:257-259.
21. Coleman J. Sleep Studies. Current Techniques and Future Trends. Otolaryngol Clin North Am. 1999;32:195-210.
22. Strohl KP. Timing, number and complexities of sleep studies. Sleep Breathing. 1997;2:45-49.
23. Thorpy M. The Clinical Use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep. 1992;15:268-276.
24. Mitler M, Carskadon M, Hirshkowitz M. Evaluating sleepiness. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:1251-1257.
25. Doghramji K, Mitler MM, Sangal RB, et al. A normative study of the maintenance of wakefulness test (MWT). Electroencephalogr Clin Neurophysiol. 1997;103:554-562
26. Littner M, Kushida C, Anderson W, et al. Practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002. Sleep. 2003;26:337-341.
27. Thorpy M, Chesson A, Derderian S. Practice parameters for the use of actigraphy in the clinical assessment of sleep disorders. Sleep. 1995:18:285-287.
28. Littner M, Kushida CA, Anderson WM, et al. practice parameters for the role of actigraphy in the study of sleep and circadian rhythms: an update for 2002. Sleep. 2003;26:337-341.
29. Ware J, Hirshkowitz M. Assessment of sleep-related erections. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:1231-1237.
30. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab. 2001;86:3787-3794.
31. Rodenbeck A, Hajak G. Neuroendocrine dysregulation in primary insomnia. Rev Neurol (Paris). 2001;157:S57-S61.
32. Vgontzas, AN, Zoumakis M, Papanicolaou DA, et al. Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism. 2002;51:887-892.
33. Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin. 2002;31:15-36.
34. Morin C, Hauri P, Espie C, et al. Non-pharmacologic treatment of chronic insomnia. Sleep. 1999;22:1134-1156.
35. Petit L, Azad N, Byszewski A, et al. Non-pharmacological management of primary and secondary insomnia among older people: review of assessment tools and treatments. Age Ageing. 2003;32:19-25.
36. Kales A, Kales R. Evaluation and Treatment of Insomnia. New York, NY: Oxford Press; 1984:2-320.
37. Buysee DJ, Reynolds CF 3rd, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatr Res. 1989;28:193-213.
38. Holbrook A, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Assoc J. 2000;162:225-233.
39. Shorr RI, Robin DW. Rational use of benzodiazepines in the elderly. Drugs Aging. 1994;4:9-20.
40. Vgontzas AN, Kales A, Bixler EO. Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology. 1995;51:205-223.
41. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem, and zaleplon. Drug Saf. 2003;26:261-282.
42. Harvey AG. A cognitive model of insomnia. Behav Res Ther. 2002;40:869-893.
43. Johnson LC, Spinweber CL. Quality of sleep and performance in the Navy: a longitudinal study of good and poor sleepers. In: Guilleminault C, Lugaresi E, eds. Sleep/wake Disorders: Natural History, Epidemiology, and Long-term Evolution. New York, NY: Raven Press; 1983.
44. Backhaus J, Hohagen F, Voderholzer U, Riemann D. Long-term effectiveness of a short-term cognitive-behavioral group treatment for primary insomnia. Eur Arch Psychiatry Clin Neurosci. 2001;251:35-41.
45. Kales JD, Kales A, Bixler EO, et al. Biopsychobehavioral correlates of insomnia, V. Clinical and behavioral correlates. Am J Psychiatry. 1994;141:1371-1376.
46. Mamber R, Kuo T. Cognitive-behavioral therapies for insomnia. In: Chiong, Sateia, Carskadon, eds. Sleep Medicine. Philadelphia, Pa: Hanley & Belfus; 2002:177-185.
47. Dahl R. The Interface between Sleep Disorders and Behavioral/Emotional Disturbances Cases. Proceedings in the 9th Annual Course in Pediatric Sleep Medicine by the School of Sleep Medicine, Palo Alto, Calif, March 22-26, 2003.
48. Guilleminault C, Clerk A, Black J, et al. Nondrug treatment trials in psychophysiologic insomnia. Arch Intern Med. 1995;155:838-844.
49. Baker S, Zee P. Circadian disorders of the sleep-wake cycle. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:606-614.
50. Turek F, Dugovic C, Zee P. Current Understanding of the circadian clock and the clinical implications for neurological disorders. Arch Neurol. 2001;58:1781-1787.
51. Skene DJ. Optimization of light and melatonin to phase-shift human circadian rhythms. J Neuroendocrinol. 2003;15:438-441.
52. Rivkees S. Mechanisms and clinical significance of circadian rhythms in children. Curr Opin Pediatr. 2001;13:352-357.
53. Cardinali DP, Brusco LI, Lloret SR, Furio AM. Melatonin in sleep disorders and jet-lag. Neuroendocrinol Lett. 2002;23(suppl 1):9-13.
54. Ondze B, Espa F, Ming LC, et al. Advanced sleep phase syndrome. Rev Neurol (Paris). 2001;157(II Pt 2):S130-S134.
55. Monk T. Shift work. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:600-605.
56. Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. Sleep Med Rev. 2002;6:407-420.
57. Quera-Salva MA. Rapid shift in sleep time and acrophase of melatonin secretion in short shift work schedule. Sleep. 1996;19:539-543.
58. Van Reeth O, Mennuni G. Fatigue and sleep: the point of view of the chronobiologist. Rev Med Brux. 2002;23:A288-A293.
59. Horowitz TS, Tanigawa T. Circadian-based new technologies for night workers. Ind Health. 2002;40:223-236.
60. Purnell MT, Feyer AM, Herbison GP The impact of a nap opportunity during the night shift on the performance and alertness of 12-h shift workers. J Sleep Res. 2002;11:219-227.
61. Meoli A, Casey K, Clark R, et al. Hypopnea in sleep-disordered breathing in adults. Sleep. 2001;24:469-470.
62. Guilleminault C, Stoohs R, Clerk A, Cetel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway resistance syndrome. Chest. 1993;104:781-787.
63. Black JE, Guiileminault C, Colrain IM, Carrillo O. Upper airway resistance syndrome. Central electroencephalographic power and changes in breathing effort. Am J Respir Crit Care Med. 2000;162:406-411.
64. Guilleminault C, Kim YD, Palombini L, Li K, Powell N. Upper airway resistance syndrome and its treatment. Sleep. 2000;23(suppl 4):S197-S200.
65. Schecter M and the Section on Pediatric Pulmonology Subcommittee on Obstructive Sleep Apnea Syndrome. Technical report: diagnosis and management of childhood obstructive sleep apnea. Pediatrics. 2002;109:e69.
66. Bower C, Gungor A. Update on the pediatric airway. Pediatric obstructive sleep apnea. Otolaryngol Clin North Am. 2000;33:49-75.
67. Guilleminault C, Pelayo R, Leger D, Clerk A, Bocian R. Recognition of sleep-disordered breathing in children. Pediatrics. 1996;98:871-882.
68. Chervin RD, Archbold KH, Dillon JE, et al. Inattention, hyperactivity, and symptoms of sleep-disordered breathing. Pediatrics. 2002;109:449-4S6.
69. Corkum P, Muldofsky H, Hogg-Johnson S, Humphries T, Tannock R. Sleep problems in children with attention deficit/hyperactivity disorder: impact of subtype, comorbidity, and stimulant medication. J Am Acad Child Adoles Psychiatry. 1999;38:1285-1293.
70. Loube DI, Gay PC, Strohl KP, et al. Indications for positive airway pressure treatment of adult obstructive sleep apnea patients. A consensus statement. Chest. 1999;115:863-866.
71. Mosk S. Self-reported depressive symptomatology, mood ratings, and treatment outcome in sleep disorder patients. J Clin Psychol. 1989;45:51-60.
72. Sforza E, Lugaresi, E. Daytime sleepiness and nasal continuous positive airway pressure therapy in obstructive sleep apnea syndrome patients; effects of chronic treatment and 1-night therapy withdrawal. Sleep. 1995;18:195-201.
73. Redline S, Adams N, Strauss ME, et al. Improvement of mild sleep-disordered breathing with CPAP compared with conservative therapy. Am J Respir Crit Care Med. 1998;157:858-865.
74. Kribbs NB, Pack AI, Kline LR, et al. Effects of one night without nasal CPAP treatment on sleep and sleepiness in patients with obstructive sleep apnea. Am Rev Respir Dis. 1993;14:1162-1168.
75. Rajagopal KR, Bennett LL, Dillard TA, Tellis CJ, Tenholder MF: Overnight nasal CPAP improves hypersomnolence in sleep apnea. Chest. 1986;90:172-176.
76. Engleman HM, Martin SE, Deary IJ, Douglas NJ. Effects of continuous positive airway pressure treatment on daytime function in sleep apnoea/ hypopnoea syndrome. Lancet. 1994;343:572-575.
77. Downey R 3rd, Perkin RM, MacQuarrie J. Nasal continuous positive airway pressure use in children with obstructive sleep apnea younger than 2 years of age. Chest. 2000;117:1608-1612.
78. McNamara F, Sullivan C. Obstructive sleep apnea in infants and its management with nasal continuous positive airway pressure. Chest. 1999;116:10-16.
79. Anstead M, Phillips B, Buch K. Tolerance and intolerance to continuous positive airway pressure. Curr Opin Pulm Med. 1998;4:351-354.
80. Strollo PJ Jr, Sanders MH, Atwood CW. Positive pressure therapy. Clin Chest Med. 1998;19:55-68.
81. Hoffstein V, Viner S, Mateika S, Conway J. Treatment of obstructive sleep apnea with nasal continuous positive airway pressure patient compliance, perception of benefits, and side effects. Am Rev Respir Dis. 1992;145:841-845.
82. Issa FG, Sullivan CE. Reversal of central sleep apnea using nasal CPAR Chest 1984;90:165-171.
83. Rauscher H, Popp W, Wanke T, Zwick H. Acceptance of CPAP therapy for sleep apnea. Chest. 1991;100:1019-1023.
84. Rolfe I, Olson LG, Saunders NA. Long-term acceptance of continuous positive airway pressure in obstructive sleep apnea. Am Rev Respir Dis. 1991;144:1130-1133.
85. Nino-Murcia G, McCann CC, Bliwise DL, Guilleminault C, Dement WC. Compliance and side effects in sleep apnea patients treated with nasal continuous positive airway pressure. West J Med. 1989;150:165-169.
86. Sanders MH, Gruendl CA, Rogers RM. Patient compliance with nasal CPAP therapy for sleep apnea. Chest. 1986;90:330-333.
87. Waldhorn, RE, Herrick TW, Nguyen MC, O'Donnell AE, Sodero J, Potolicchio SJ. Long-term compliance with nasal continuous positive airway pressure therapy of obstructive sleep apnea. Chest. 1990;97:33-38.
88. Littner M, Hirshkowitz M, Davila D, et al. Practice parameters of the use of auto-titrating continuous positive airway pressure devices for titrating pressures and treating adult patients with obstructive sleep apnea syndrome. Sleep. 2002;25:143-147.
89. Berry RB. The use of auto-titrating continuous positive airway pressure for treatment of adult obstructive sleep apnea. Sleep. 2002;25:148-173.
90. American Sleep Disorders Association. Practice parameters for the treatment of obstructive sleep apnea in adults: the efficacy of surgical modifications of the upper airway. Sleep. 1996;19:152-155.
91. Rama AN, Tekwani SH, Kushida CA. Sites of obstruction in obstructive sleep apnea. Chest. 2002;122:1139-1147.
92. Sher A, Schechtman K, Piccirillo J. The efficacy of surgical modifications of the upper airway in adults with obstructive sleep apnea syndrome. Sleep. 1996;19:156-177.
93. Loube D. Technologic advances in the treatment of obstructive sleep apnea syndrome. Chest. 1999;116:1426-1433.
94. Riley R, Powell N, Li K, Guilleminault C. Surgical therapy for obstructive sleep apnea-hypopnea syndrome. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:913-929.
95. Powell N, Riley R, Guilleminault C. Radiofrequency tongue base reduction in sleep-disordered breathing. Otolaryngol Head Neck Surg. 1999;120:656-664.
96. Riley R. Powell-Riley Stanford surgical protocol. Proceedings of the Conference on Contemporary Surgical Concepts and Techniques in Snoring and Sleep Disordered Breathing. Burlingame, Calif. April 11-12, 2003.
97. Montplaisir J, Nicolas A, Godbout R, Walters A. Restless legs syndrome and periodic limb movement disorder. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:742-752.
98. Hening WA. Restless legs syndrome: a sensorimotor disorder of sleep/wake motor regulation. Curr Neurol Neurosci Rep. 2002;2:186-196.
99. Stiasny K, Oertel WH, Trenkwalder C. Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev. 2002;6:247-251.
100. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole. Neurology. 1999;52:938-943.
101. Allen RP, Mignot E, Ripley B, Nishino S, Earley CJ. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology. 2002;59:639-641.
102. Chokroverty S, Jankovic J. Restless legs syndrome. Neurology. 1999;52:907.
103. 11C-raclopride PET studies. Neurology. 1999;52:932-937.
104. 2-receptor alteration. Eur Arch Psychiatry Clin Neurosci. 1995;245:8-10.
105. Saletu M, Anderer P, Saletu B, et al. EEG mapping in patients with restless legs syndrome as compared with normal controls. Psychiatry Res. 2002;115:49-61.
106. Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 1999;22:970-999.
107. Chesson A, Wise M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep. 1999;22:961-968.
108. Comella C. Restless legs syndrome. Treatment with dopaminergic agents. Neurology. 2002;58:S87-S92.
109. Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep. 1993;16:327-332.
110. Kaplan PW, Allen RP, Buchholz DW, Walters, JK. A double-blind placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep. 1993;16:717-723.
111. Montagna P, Sassoli de Bianchi L, Zucconi M, et al. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand. 1984;69:428-430.
112. Boghen D, Lamothe L, Elie R, et al. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci. 1986;13:245-247.
113. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis. 2001;38:104-108.
114. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin. A double-blind, cross-over study. Neurology. 2002;59:1573-1579.
115. Telstaad W, Sorensen O, Larsen S, et al. Treatment of the restless legs syndrome with carbamazepine: a double-blind study. BMJ (Clin Res Ed). 1984;288:444-446.
116. Wagner ML, Walters AS, Coleman RG, Hening WA, Grasing K, Chokroverty S. Randomized, double-blind placebo-controlled study of clonidine in restless legs syndrome. Sleep. 1996;19:S2-S8.
117. Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology. 1993;43:443-445.
118. Guilleminault C, Anagnos A. Narcolepsy. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:676-686.
119. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol. 2001;18:78-105.
120. Stores G. Recognition and management of narcolepsy. Arch Dis Child. 1999;81:S19-S24.
121. Gerhardstein R, Day R, Rosenthal L. Narcolepsy and other causes of excessive daytime sleepiness. Respir Care Clin N Am. 1999;S:427-446.
122. Guilleminault C, Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment, and follow-up. Paediatr Drugs. 2000;2:1-9.
123. Krahn LE, Black JL, Silber MH. Krahn, L. Narcolepsy: new understanding of irresistible sleep. Mayo Clinic Proc. 2001;76:185-194.
124. Aldrich M. Narcolepsy. N Engl J Med. 1990;323:389-394.
125. Black J. Narcolepsy: evaluation and management. CNS News Special Ed. 2001:25-29.
126. Guilleminault C, Wilson RA, Dement WC. A study on cataplexy. Arch Neurol. 1974;31:255-261.
127. Guilleminault C, Anders TF. The pathophysiology of sleep disorders in pediatrics. Part II. Sleep disorders in children. Adv Pediatr. 1976;22:151-174.
128. Rubboli G, d'Orsi G, Zaniboni A, et al. A video-polygraphic analysis of the cataplectic attack. Clin Neurophysiol. 2000;111 (suppl 2):5120-5128.
129. Overeem S, Scammell T, Lammers G. Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. Curr Opin Neurol. 2002;15:739-745.
130. Mignot E, Lammers GJ, Ripley B, et al. The role for cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59:1553-1562.
131. Krahn LE, Pankratz VS, Oliver L, Boeve BF, Silber MH. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1 *0602 status. Sleep. 2002;25:733-736.
132. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res. 2002;11:91-93.
133. Mitler MM, Aldrich MS, Koob GF, Zarcone VP. Narcolepsy and its treatment with stimulants: ASDA standards of practice. Sleep. 1994;17:352-371.
134. Parkes D. Introduction to the mechanism of action of different treatments of narcolepsy. Sleep. 1994;17(8 suppl):S93-S96.
135. Littner M, Johnson SF, McCall WV, et al. Standards of Practice Committee. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep. 2001;24:451-466.
136. Scamell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol. 2003;53:154-166.
137. Thorpy MJ, Snyder M, Aloe FS, Ledereich PS, Starz KE. Short-term triazolam use improves nocturnal sleep of narcoleptics. Sleep. 1992;15:212-216.
138. Bassetti C, Aldrich M. Idiopathic hypersomnia. A series of 42 patients. Brain. 1997;120:1423-1435.
139. Guilleminault C, Brooks S. Idiopathic hypersomnia: a neurological dilemma. Sleep Med Rev. 2001;5:347-349.
140. Broughton R. NREM arousal parasomnias. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:687-692.
141. Kales A, Soldatos CR, Bixler EO, et al. Hereditary factors in sleepwalking and night terrors. Br J Psychiatry. 1980;137:111-118.
142. Abe K, Amatomi M, Oda N. Sleepwalking and recurrent sleep talking in children of childhood sleepwalkers. Am J Psychiatry. 1984;141:800-801.
143. Guilleminault C, Poyares D, Abat F, Palombini L. Sleep and wakefulness in somnambulism. A spectral analysis study. J Psychosom Res. 2001;51:411-416.
144. Guilleminault C, Palombini L, Pelayo R, Chervin R. Sleepwalking and sleep terrors in prepubertal children: what triggers them? Pediatrics. 2003;111:e17-e25.
145. Guilleminault C, Moscovich A, Leger D. Forensic sleep medicine and nocturnal wandering and violence. Sleep. 1995;15:173-184.
146. Broughton RJ, Shimuzu T. Sleep-related violence: a medical and forensic challenge. Sleep. 1995;18:727-730.
147. Olson E, Boeve B, Silbert M. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. Brain. 2000;123:331-339.
148. Mahowald M, Schenk C. Medical-legal aspects of sleep medicine. Neurol Clin. 1999;17:215-234.
149. Mahowald M, Schenk C. REM sleep parasomnias. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine. 3rd ed. Philadelphia, Pa: WB Saunders; 2000:724-741.
150. Ferini-Strambi L, Zucconi M. REM sleep behavior disorder. Clin Neurophysiol. 2000;111 (suppl 2):S136-S140.
151. 5chenck C, Bundlie S, Ettinger M, Mahowald M. Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep. 1986;9:293-308.
152. Silber M. REM sleep behavior disorder associated with barbiturate withdrawal. APSS Abstract. Sleep Res. 1996;25:371.
153. Husain A, Miller P, Carwile S. REM sleep behavior disorder: potential relationship to post-traumatic stress disorder. J Clin Neurophysiol. 2001;18:148-157.
154. Onofrj M, Luciano AL, Thomas A, et al. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology. 2003;60:113-115.
155. Schutte S, Doghramji K. REM behavior disorder seen with venlafaxine (Effexor). APSS Abstract. Sleep Res. 1996;25:364.
156. Shirakawa S, Takeuchi N, Uchimura N, et al. Study of image findings in rapid eye movement sleep behavioural disorder. Psychiatry Clin Neurosci. 2002;S6:291-292.
157. Albin RL, Koeppe RA, Chervin RD, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology. 2000;55:1410-1412
158. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donezepil: a report of three cases. Neurology. 2000;55:870-871.
159. Bamford C. Carbamazepine in REM sleep behavior disorder. Sleep. 1993;16:33.
160. Mike ME, Kranz AJ. MAOI suppression of RBD refractory to clonazepam and other agents. Sleep Res. 1996;25:63.
161. Takeuchi N, Uchimura N, Hashizume Y, et al. Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin Neurosci. 2001;55:267-279.
162. Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior patients: an open-labeled pilot study on the possible influence of melatonin on REM sleep regulation. Mov Disord. 1999;14:507-511.